Neurocrine Bioscienc (NBIX)
125.44 -0.45 (-0.36%)
Neurocrine Biosciences is a biopharmaceutical company focused on developing innovative treatments for neurological and endocrine diseases. The company conducts research and creates drug therapies aimed at addressing the unmet medical needs of patients suffering from conditions such as movement disorders, psychiatric disorders, and hormonal disorders. Through a combination of scientific expertise and cutting-edge technology, Neurocrine strives to enhance patient outcomes and improve quality of life, while expanding its pipeline of therapeutic options in the field of neuroscience and endocrinology.
Previous Close | 125.89 |
---|---|
Open | 125.41 |
Bid | 122.87 |
Ask | 128.55 |
Day's Range | 125.26 - 126.98 |
52 Week Range | 110.95 - 157.98 |
Volume | 751,328 |
Market Cap | 12.69B |
PE Ratio (TTM) | 33.45 |
EPS (TTM) | 3.8 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 972,206 |
News & Press Releases
For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering.chartmill.com
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a growth opportunity that won't break the bank.
Via Chartmill · December 3, 2024
NASDAQ:NBIX qualifies as a high growth stock and is consolidating.chartmill.com
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock?
Via Chartmill · November 28, 2024
NASDAQ:NBIX stands out as a stock that provides good value for the fundamentals it showcases.chartmill.com
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is an undervalued gem with solid fundamentals.
Via Chartmill · November 19, 2024
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.chartmill.com
Via Chartmill · November 12, 2024
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfoliobenzinga.com
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience strategy and boosting competition for Cobenfy.
Via Benzinga · November 12, 2024
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move.chartmill.com
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Standout High-Growth Stock in a Consolidation Phase.
Via Chartmill · September 19, 2024
Decoding 19 Analyst Evaluations For Neurocrine Biosciencesbenzinga.com
Via Benzinga · September 9, 2024
NASDAQ:NBIX, a growth stock which is not overvalued.chartmill.com
Via Chartmill · September 9, 2024
In-Depth Examination Of 20 Analyst Recommendations For Neurocrine Biosciencesbenzinga.com
Via Benzinga · October 29, 2024
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.chartmill.com
Via Chartmill · October 22, 2024
NASDAQ:NBIX appears to be flying under the radar despite its strong fundamentals.chartmill.com
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill · October 21, 2024
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation.chartmill.com
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via Chartmill · October 11, 2024
Critical Insights From Neurocrine Biosciences Analyst Ratings: What You Need To Knowbenzinga.com
Via Benzinga · October 4, 2024
"Rule Breaker Investing" Market Cap Game Show: Throwdowns & Long-Term Winsfool.com
Via The Motley Fool · September 30, 2024
Despite its growth, NASDAQ:NBIX remains within the realm of affordability.chartmill.com
In the world of growth stocks, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) shines as a value proposition.
Via Chartmill · September 30, 2024
For those who appreciate value investing, NASDAQ:NBIX is a compelling option with its solid fundamentals.chartmill.com
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is probably undervalued for the fundamentals it is displaying.
Via Chartmill · September 26, 2024
Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpointbenzinga.com
Neurocrine Biosciences announced that its ERUDITE Phase 2 trial for luvadaxistat failed to meet its primary endpoint in treating cognitive impairment in schizophrenia. The company will halt development and focus on advancing other schizophrenia and depression candidates.
Via Benzinga · September 13, 2024
Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio?benzinga.com
10 worst performing large-cap stocks in August: Super Micro, Dollar General, Snap, PDD Holdings, Intel, Tencent Music, Gold Fields, Charles River, Moderna, Neurocrine Biosciences.
Via Benzinga · September 8, 2024
Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag.chartmill.com
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill · September 5, 2024
Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio?benzinga.com
10 worst performing large-cap stocks in the last week. Dollar General, Super Micro Computer, Okta, Pure Storage, Neurocrine Biosciences among them.
Via Benzinga · September 2, 2024
Why Neurocrine Biosciences Stock Was Tumbling This Weekfool.com
The company promises to advance a top investigational drug to late-stage testing, but investors might not think that's a fine idea.
Via The Motley Fool · August 30, 2024
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Reviewinvestors.com
Via Investor's Business Daily · August 30, 2024
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stockbenzinga.com
Neurocrine Biosciences reports positive Phase 2 trial results for NBI-1117568 in adults with schizophrenia, showing significant reduction in PANSS scores with a 20 mg dose. Piper Sandler upgrades the stock, citing potential in the antipsychotic market.
Via Benzinga · August 29, 2024